Developer docs
API playgroundTry for free, no card

Search company profiles

IntelGenX

Full company profile

uuid00059hs

Namestring
IntelGenX
Legal namestring
IntelGenx Technologies Corp.
Websiteurl
intelgenx.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

IntelGenx Technologies Corp., now operating as Nualtis, is a Canadian specialty pharmaceutical company headquartered in Saint Laurent, Quebec, founded in 2002. The company develops and manufactures oral thin film (OTF) drug delivery technologies, organized around two proprietary platforms: VersaFilm® for human health applications and VetaFilm® for animal health. The core technology enables drug delivery through oral mucosal absorption, offering enhanced bioavailability, reduced first-pass metabolism, precise dose control, and water-free administration — addressing limitations of conventional tablets and capsules, particularly for pediatric, geriatric, and veterinary patients. IntelGenx holds over 30 US patents covering formulations and manufacturing processes.

The company operates a B2B partnership model, monetizing its technology through out-licensing of existing products, co-development agreements with pharmaceutical partners (from concept to commercialization), and contract GMP manufacturing services. Revenue is generated through licensing royalties, milestone payments, co-development fees, and manufacturing service contracts, with all arrangements conducted on a quote-based, non-publicly disclosed basis. Customer segments include human health pharmaceutical companies, animal health/veterinary pharmaceutical companies, and licensing partners. The company provides vertically integrated capabilities spanning R&D, analytical method development, regulatory submissions to FDA/EMA/global agencies, cGMP manufacturing from pilot to commercial scale, and QA release with serialization support.

Named commercial partners include US Exeltis & Xiromed, Gensco Pharma, and atai Life Sciences AG, the last of which is both a strategic shareholder (with board representation) and a pipeline collaborator. IntelGenx has sustained a multi-year funding relationship with AtaiBeckley/atai since 2021, with the most recent round in December 2023 totaling US$750,000 via convertible notes and warrants, and an option for additional investment through August 2026. The company trades on OTCQX under the symbol IGXT and is led by CEO Dr. Michael Raven, supported by CSO Nadine Paiement, VP Quality Nina Pourhassan, and BD Lead & General Counsel Tommy Kenny.

Short descriptiontext

IntelGenx (now Nualtis) is a Canadian pharmaceutical technology company that develops and manufactures proprietary oral thin film drug delivery platforms — VersaFilm® for human health and VetaFilm® for animal health — via B2B licensing, co-development, and contract GMP manufacturing partnerships with pharmaceutical companies globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaint Laurent, Canada
HQ citystring
Saint Laurent
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oral thin film technology, pharmaceutical drug delivery, oral transmucosal films, GMP contract manufacturing, sublingual drug delivery
Industry2 codes
PRIMARYHLAIABAF
Ophthalmic & Otic Generics
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pharmaceutical Drug Delivery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Co-development Partnerships
TypeLicensing Royalties
Description

IntelGenx partners with pharmaceutical companies to co-develop and commercialize oral film products, generating revenue through licensing deals, co-development fees, and milestone payments. The company also offers its existing portfolio of products available for out-licensing.

nualtis.com
2Contract Manufacturing Services
TypeProfessional Services
Description

The company provides GMP manufacturing services to pharmaceutical partners, offering analytical, R&D, and manufacturing capabilities from pilot scale to commercial production. Revenue is generated through service contracts and manufacturing fees.

nualtis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1VersaFilm®
Description

Proprietary platform for human health oral film products enabling enhanced bioavailability, systemic absorption, and precision dosing through oral mucosal delivery.

nualtis.com
+1 more record
Core offering1 text field

IntelGenx (operating as Nualtis) develops and manufactures proprietary oral thin film drug delivery platforms for pharmaceutical and veterinary applications. The company operates two product platforms — VersaFilm® for human health and VetaFilm® for animal health — and provides end-to-end services including R&D, GMP-compliant contract manufacturing, and analytical and regulatory support to pharmaceutical partners through licensing, co-development, and out-licensing arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Faster onset of action and reduced dosage requirements compared to conventional tablets or capsules
+1 more record
Product overview1 text field

Nualtis (formerly IntelGenx) offers a platform-based product architecture built around two proprietary oral film technology platforms: VersaFilm® for human health applications and VetaFilm® for animal health. The company operates as both a product developer and a service provider, offering pharmaceutical companies end-to-end support through research and development, GMP manufacturing, and analytical and regulatory services. The VersaFilm® platform delivers medications directly through oral mucosal lining for enhanced bioavailability and faster onset, while the VetaFilm® platform provides palatable, room-stable films for animal dosing. With over 30 US patents, the company focuses on novel drug delivery through innovative oral thin film technology for both human and veterinary applications.

Product and service1 record
1VersaFilm® Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1US Exeltis & Xiromed
Strategic tierCoreTypeStrategic or Co-development Partner
Description

US Exeltis & Xiromed partners with Nualtis to leverage the thin-film platform for complex formulations, turning ideas into practical solutions and providing patients with high-quality, affordable treatment options. CEO Robert Spina has publicly endorsed the partnership.

nualtis.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Gensco Pharma partners with Nualtis to access world-class oral film delivery technology and manufacturing strength, aiming to bring more accessible treatments to patients. CEO Dr. Paul Zimmerman has publicly endorsed the partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Cure Pharmaceutical develops oral thin film drug delivery technologies (CureFilm) and offers contract manufacturing of oral dissolvable films. It competes directly with Nualtis in offering licensing, co-development, and GMP manufacturing services centered on oral film platforms.

TypeDirect peer
Description

ZIM Laboratories is an India-based specialty pharmaceutical company developing oral thin film (Thinoral) and other innovative drug delivery platforms. It offers formulation, licensing, and manufacturing services comparable to Nualtis' VersaFilm® offering and targets similar global pharma partners.

3Tapemark
TypeDirect peer
Description

Tapemark is a contract developer and manufacturer specializing in transdermal patches and oral thin films, serving pharmaceutical and consumer health companies. It overlaps directly with Nualtis in GMP oral film manufacturing and co-development services.

TypeDirect peer
Description

BioDelivery Sciences International (now part of Collegium Pharmaceutical) developed oral transmucosal film products such as Bunavail using its BEMA® delivery technology. It is a direct historical peer in oral thin film drug delivery, particularly in pain and addiction therapeutics.

TypeDirect peer
Description

Aquestive Therapeutics is a direct competitor in oral soluble film drug delivery, with proprietary PharmFilm® technology and a portfolio that includes treatments for allergy, migraine, and seizure rescue. Both companies commercialize oral thin film platforms to global pharma partners and compete for similar co-development mandates.

TypeBroad incumbent
Description

Catalent is a large global CDMO offering oral film, softgel, and other drug delivery capabilities as part of a broad pharmaceutical services portfolio. While not specialized in oral films alone, it competes with Nualtis for partnership and manufacturing mandates from mid-sized and large pharma companies.

TypeDirect peer
Description

LTS Lohmann Therapie-Systeme is a leading global manufacturer of oral thin film and transdermal drug delivery systems, serving as both a CDMO and licensor to pharmaceutical companies. It directly competes with Nualtis in formulation expertise, patent depth, and contract manufacturing services for oral film products.

TypeDirect peer
Description

Adhex Pharma develops and manufactures oral thin films and transdermal patches, serving pharmaceutical companies globally. It is a direct peer to Nualtis in formulation, licensing, and GMP manufacturing of oral film-based pharmaceutical products.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds20 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IntelGenX

Pharmaceutical Drug Deliveryintelgenx.com

IntelGenx (now Nualtis) is a Canadian pharmaceutical technology company that develops and manufactures proprietary oral thin film drug delivery platforms — VersaFilm® for human health and VetaFilm® for animal health — via B2B licensing, co-development, and contract GMP manufacturing partnerships with pharmaceutical companies globally.

What IntelGenX does

IntelGenx Technologies Corp., now operating as Nualtis, is a Canadian specialty pharmaceutical company headquartered in Saint Laurent, Quebec, founded in 2002. The company develops and manufactures oral thin film (OTF) drug delivery technologies, organized around two proprietary platforms: VersaFilm® for human health applications and VetaFilm® for animal health. The core technology enables drug delivery through oral mucosal absorption, offering enhanced bioavailability, reduced first-pass metabolism, precise dose control, and water-free administration — addressing limitations of conventional tablets and capsules, particularly for pediatric, geriatric, and veterinary patients. IntelGenx holds over 30 US patents covering formulations and manufacturing processes.

The company operates a B2B partnership model, monetizing its technology through out-licensing of existing products, co-development agreements with pharmaceutical partners (from concept to commercialization), and contract GMP manufacturing services. Revenue is generated through licensing royalties, milestone payments, co-development fees, and manufacturing service contracts, with all arrangements conducted on a quote-based, non-publicly disclosed basis. Customer segments include human health pharmaceutical companies, animal health/veterinary pharmaceutical companies, and licensing partners. The company provides vertically integrated capabilities spanning R&D, analytical method development, regulatory submissions to FDA/EMA/global agencies, cGMP manufacturing from pilot to commercial scale, and QA release with serialization support.

Named commercial partners include US Exeltis & Xiromed, Gensco Pharma, and atai Life Sciences AG, the last of which is both a strategic shareholder (with board representation) and a pipeline collaborator. IntelGenx has sustained a multi-year funding relationship with AtaiBeckley/atai since 2021, with the most recent round in December 2023 totaling US$750,000 via convertible notes and warrants, and an option for additional investment through August 2026. The company trades on OTCQX under the symbol IGXT and is led by CEO Dr. Michael Raven, supported by CSO Nadine Paiement, VP Quality Nina Pourhassan, and BD Lead & General Counsel Tommy Kenny.

IntelGenX firmographics

Firmographics
Name
IntelGenX
Legal name
IntelGenx Technologies Corp.
Website
https://intelgenx.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
IntelGenx (now Nualtis) is a Canadian pharmaceutical technology company that develops and manufactures proprietary oral thin film drug delivery platforms — VersaFilm® for human health and VetaFilm® for animal health — via B2B licensing, co-development, and contract GMP manufacturing partnerships with pharmaceutical companies globally.
Ownership category
akta.pro rank

IntelGenX industry classification

Industry
Product category
Pharmaceutical Drug Delivery
NAICS
Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIABAF
Ophthalmic & Otic Generics
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • Oral thin film technology
  • Pharmaceutical drug delivery
  • Oral transmucosal films
  • GMP contract manufacturing
  • Sublingual drug delivery

Where IntelGenX is headquartered

Location

Headquarters

HQ city
Saint Laurent
HQ country
Canada
HQ region
North America

Markets served

IntelGenX business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Licensing and Co-development Partnerships: IntelGenx partners with pharmaceutical companies to co-develop and commercialize oral film products, generating revenue through licensing deals, co-development fees, and milestone payments. The company also offers its existing portfolio of products available for out-licensing.
  2. Contract Manufacturing Services: The company provides GMP manufacturing services to pharmaceutical partners, offering analytical, R&D, and manufacturing capabilities from pilot scale to commercial production. Revenue is generated through service contracts and manufacturing fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

IntelGenX product offering

Product offering

Core offering

IntelGenx (operating as Nualtis) develops and manufactures proprietary oral thin film drug delivery platforms for pharmaceutical and veterinary applications. The company operates two product platforms — VersaFilm® for human health and VetaFilm® for animal health — and provides end-to-end services including R&D, GMP-compliant contract manufacturing, and analytical and regulatory support to pharmaceutical partners through licensing, co-development, and out-licensing arrangements.

Product overview

Nualtis (formerly IntelGenx) offers a platform-based product architecture built around two proprietary oral film technology platforms: VersaFilm® for human health applications and VetaFilm® for animal health. The company operates as both a product developer and a service provider, offering pharmaceutical companies end-to-end support through research and development, GMP manufacturing, and analytical and regulatory services. The VersaFilm® platform delivers medications directly through oral mucosal lining for enhanced bioavailability and faster onset, while the VetaFilm® platform provides palatable, room-stable films for animal dosing. With over 30 US patents, the company focuses on novel drug delivery through innovative oral thin film technology for both human and veterinary applications.

Differentiator

Problem solved

Functional benefit

Brands

  • VersaFilm®: Proprietary platform for human health oral film products enabling enhanced bioavailability, systemic absorption, and precision dosing through oral mucosal delivery.
  • VetaFilm®

Products and services

  • VersaFilm® Platform

Quantifiable outcome

  • Faster onset of action and reduced dosage requirements compared to conventional tablets or capsules
  • +1 more outcomes

Companies that use IntelGenX

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

IntelGenX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

IntelGenX partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • US Exeltis & XiromedcoreStrategic or Co-development PartnerUS Exeltis & Xiromed partners with Nualtis to leverage the thin-film platform for complex formulations, turning ideas into practical solutions and providing patients with high-quality, affordable treatment options. CEO Robert Spina has publicly endorsed the partnership.
  • Gensco PharmacoreStrategic or Co-development PartnerGensco Pharma partners with Nualtis to access world-class oral film delivery technology and manufacturing strength, aiming to bring more accessible treatments to patients. CEO Dr. Paul Zimmerman has publicly endorsed the partnership.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

IntelGenX competitors and assessment

Company assessment

Direct peers

  • Cure Pharmaceutical (CureRx): Cure Pharmaceutical develops oral thin film drug delivery technologies (CureFilm) and offers contract manufacturing of oral dissolvable films. It competes directly with Nualtis in offering licensing, co-development, and GMP manufacturing services centered on oral film platforms.
  • ZIM Laboratories: ZIM Laboratories is an India-based specialty pharmaceutical company developing oral thin film (Thinoral) and other innovative drug delivery platforms. It offers formulation, licensing, and manufacturing services comparable to Nualtis' VersaFilm® offering and targets similar global pharma partners.
  • Tapemark: Tapemark is a contract developer and manufacturer specializing in transdermal patches and oral thin films, serving pharmaceutical and consumer health companies. It overlaps directly with Nualtis in GMP oral film manufacturing and co-development services.
  • BioDelivery Sciences International: BioDelivery Sciences International (now part of Collegium Pharmaceutical) developed oral transmucosal film products such as Bunavail using its BEMA® delivery technology. It is a direct historical peer in oral thin film drug delivery, particularly in pain and addiction therapeutics.
  • Aquestive Therapeutics: Aquestive Therapeutics is a direct competitor in oral soluble film drug delivery, with proprietary PharmFilm® technology and a portfolio that includes treatments for allergy, migraine, and seizure rescue. Both companies commercialize oral thin film platforms to global pharma partners and compete for similar co-development mandates.
  • LTS Lohmann Therapie-Systeme: LTS Lohmann Therapie-Systeme is a leading global manufacturer of oral thin film and transdermal drug delivery systems, serving as both a CDMO and licensor to pharmaceutical companies. It directly competes with Nualtis in formulation expertise, patent depth, and contract manufacturing services for oral film products.
  • Adhex Pharma: Adhex Pharma develops and manufactures oral thin films and transdermal patches, serving pharmaceutical companies globally. It is a direct peer to Nualtis in formulation, licensing, and GMP manufacturing of oral film-based pharmaceutical products.

Broad incumbents

  • Catalent: Catalent is a large global CDMO offering oral film, softgel, and other drug delivery capabilities as part of a broad pharmaceutical services portfolio. While not specialized in oral films alone, it competes with Nualtis for partnership and manufacturing mandates from mid-sized and large pharma companies.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

IntelGenX social profiles

Digital presence

IntelGenX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IntelGenX leadership team

Management profile

Number of profiles

Profiles5 records

IntelGenX funding detail

Funding detail

Funding overview

Funding rounds20 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IntelGenX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IntelGenX

What does IntelGenX do?

IntelGenx (operating as Nualtis) develops and manufactures proprietary oral thin film drug delivery platforms for pharmaceutical and veterinary applications. The company operates two product platforms — VersaFilm® for human health and VetaFilm® for animal health — and provides end-to-end services including R&D, GMP-compliant contract manufacturing, and analytical and regulatory support to pharmaceutical partners through licensing, co-development, and out-licensing arrangements.

Is IntelGenX a public or private company?

IntelGenX is a private company. It is classified as venture growth investor backed and is currently operating.

When was IntelGenX founded?

IntelGenX was founded in 2002. It employs 11 to 50 people.

Where is IntelGenX based?

IntelGenX is headquartered in Saint Laurent, Canada, in the North America region.

How does IntelGenX make money?

Two revenue lines are on record. Licensing and Co-development Partnerships are the primary driver. The others are contract Manufacturing Services.

Who are IntelGenX's main competitors?

Direct peers on record are Cure Pharmaceutical (CureRx), ZIM Laboratories, Tapemark, BioDelivery Sciences International, Aquestive Therapeutics, LTS Lohmann Therapie-Systeme and Adhex Pharma. Catalent is listed as a broad incumbent.

Does IntelGenX have an API?

No public API is recorded for IntelGenX.

What industry is IntelGenX in?

IntelGenX's product category is Pharmaceutical Drug Delivery. Its primary akta.pro industry code is HLAIABAF, Ophthalmic & Otic Generics, with a secondary code of HLAMAEAB, Livestock & Production Animal Therapeutics (Rx). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireIntelGenx Announces Rebranding to Nualtis, Signaling Strategic Evolution and Renewed VisionIntelGenx announced its rebrand to Nualtis, effective immediately, with the new name blending 'Nu' and 'altis' to symbolize renewal and elevation. The company, a subsidiary of atai Life Sciences, will update legal and digital materials over the coming months while continuing existing partnerships.MarketScreenerATAI Life Sciences AG completed the acquisition of the Assets of IntelGenx Technologies Corp.ATAI Life Sciences AG has completed the acquisition of the assets of IntelGenx Technologies Corp. This acquisition is significant as IntelGenx specializes in drug delivery technologies, which could enhance ATAI's pharmaceutical capabilities. The move suggests a strategic alignment in addressing unmet medical needs in the pharmaceutical sector.GlobeNewswireIntelGenx Announces Initiation of the Sale and Investment Solicitation ProcessIntelGenx Corp. received court approval for a sale and investment solicitation process, with a stalking horse bid from atai Life Sciences AG. The two-phase process has a Phase 1 bid deadline of July 15, 2024, and Ernst & Young is assisting.GlobeNewswireIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesIntelGenx Technologies filed for creditor protection under the CCAA, and the Québec Superior Court granted an initial order. The company faces a short-term liquidity crisis and will seek court approval to initiate a sale and investment solicitation process. Trading in its common shares has been halted.GlobeNewswireIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesIntelGenx Technologies Corp. filed an application under the CCAA to seek creditor protection, halting its TSX share trading. The company will seek court approval for a sale and investment solicitation process, and interim DIP financing. Three board members resigned immediately.GlobeNewswireIntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's DiseaseIntelGenx received approval from the Swedish Medical Products Agency to conduct the MONTPARK Phase 2 trial of Montelukast VersaFilm for Parkinson's disease. The randomized, double-blind, placebo-controlled study will enroll up to 90 patients on levodopa, with recruitment starting in Q1 2024. The trial is funded by a 20 million Swedish Crowns grant.PR NewswireGensco® Pharma Announces RizaFilm® Commercialization Update in the United StatesGensco Pharma, with IntelGenx, announced the anticipated launch of RizaFilm for Q1-2024, a film formulation of rizatriptan for acute migraines. The company will commercialize the 10mg film and fund expanded indications for the 5mg pediatric dose. A patient survey indicated 69% would discuss switching to RizaFilm.BioSpaceIntelGenx Receives Amended DEL License to Conduct Third-Party TestingIntelGenx Corp. received an amended Drug Establishment License from Health Canada, allowing it to conduct third-party testing. The company views this as a short-term revenue opportunity, leveraging its controlled substance license to access a broader market. Testing services will not be the primary focus, but the added revenue is welcomed.GlobeNewswireCORRECTION – IntelGenx to Participate in the 35th Annual Roth ConferenceIntelGenx Technologies Corp. will participate in the 35th Annual Roth Conference, March 12–14, 2023, in Dana Point, California. President and CFO Andre Godin will host a fireside chat on March 14 at 11:30 a.m. Pacific Time, with one-on-one investor meetings also available.GlobeNewswireIntelGenx to Participate in the 35th Annual Roth ConferenceIntelGenx Technologies Corp. will participate in the 35th Annual Roth Conference, held March 12–14, 2023, in Dana Point, California. President and CFO Andre Godin will host a fireside chat on March 14 and meet with investors. The company, a pharmaceutical films developer, will also offer one-on-one meetings.